RESOURCE LIBRARY

Advancing medicine through scientific ingenuity

RESOURCE LIBRARY

Advancing medicine science through scientific ingenuity

At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.

Filter by

CLEAR
Tuesday, July 22, 2025
Bay Area Biotech Day
Machine Learning Frameworks for Predictive PK/PD Modeling of Degraders from Fragmented Multi-Source Data
Tuesday, July 22, 2025
Bay Area Biotech Day
Rewriting Established Drug Design Rules with a CNS-Penetrant Catalytic Bruton’s Tyrosine Kinase (BTK) Degrader
Tuesday, July 22, 2025
Bay Area Biotech Day
From Incremental to Exponential: Integrating AI and DEL to Enable Discovery Across the Proteome
Tuesday, July 22, 2025
Bay Area Biotech Day
Leveraging Degrader Antibody Conjugates and Novel Ligases to Achieve Superior Delivery, Efficacy and Selectivity
Saturday, June 21, 2025
ICML
Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase Degrader, Shows High Clinical Activity and Tolerable Safety in an Ongoing Phase 1a/b Study in Patients with Waldenström Macroglobulinemia
Saturday, June 21, 2025
ICML
Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Demonstrates Rapid and Durable Clinical Responses in Relapsed/Refractory CLL: Updated Findings From an Ongoing Phase 1a Study
Thursday, June 12, 2025
EHA
Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Demonstrates Rapid and Durable Clinical Responses in Relapsed/Refractory CLL: Updated Findings From an Ongoing Phase 1a Study
Thursday, June 12, 2025
EHA
Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase Degrader, Shows High Clinical Activity and Tolerable Safety in an Ongoing Phase 1a/b Study in Patients with Waldenström Macroglobulinemia
Tuesday, April 29, 2025
American Academy of Cancer Research
Identification of Selective, Orally Bioavailable Aurora A Degraders for Treatment of Pediatric and Adult Cancers
Monday, April 28, 2025
American Association for Cancer Research (AACR) 2025 Annual Meeting
DEL-AI: Proteome-Wide In Silico Screening of Multi-Billion Compound Libraries Using Machine Learning Foundation Models